Monlumax

Molnupiravir INN

ANTIVIRAL

INDICATION

Molnupiravir is indicated for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.

DOSAGE AND ADMINISTRATION

Route of administration: Oral
The recommended dose of molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days. The safety and efficacy of molnupiravir when administered for periods longer than 5 days have not been established. Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.
OR, AS DIRECTED BY PHYSICIAN.

COMPOSITION

Monlumax 200 : Each capsule contains Molnupiravir INN 200 mg.